Arginase in retinopathy

Progress in Retinal and Eye Research

Volumn 36, Issue , 2013, Pages 260-280

  Narayanan, S Priya ^a   Rojas, Modesto ^a   Suwanpradid, Jutamas ^a   Toque, Haroldo A ^a   Caldwell, R William ^a   Caldwell, Ruth B ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arginase; Diabetic retinopathy; Nitric oxide; Oxidative stress; Peroxynitrite; Polyamine; Retinopathy of prematurity; Superoxide

Indexed keywords

ARGINASE; ARGININE; GLUTAMIC ACID; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; POLYAMINE; PROLINE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

AGING; ALLERGIC ASTHMA; ARTICLE; ATHEROSCLEROSIS; BRAIN DISEASE; CELL DEATH; CHRONIC KIDNEY DISEASE; DETOXIFICATION; DIABETIC RETINOPATHY; DNA DAMAGE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPEROXIA; HYPERTENSION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL LESION; NERVE DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPERFUSION INJURY; RETINA VEIN OCCLUSION; RETINITIS; RETROLENTAL FIBROPLASIA; SICKLE CELL ANEMIA; TRAUMATIC BRAIN INJURY; WOUND HEALING;

ARGINASE; DIABETIC RETINOPATHY; NITRIC OXIDE; OXIDATIVE STRESS; PEROXYNITRITE; POLYAMINE; RETINOPATHY OF PREMATURITY; SUPEROXIDE;

ANIMALS; ARGINASE; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; RETINAL DISEASES;

EID: 84883236637     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2013.06.002     Document Type: Article

References (253)

1. Adamis A.P., Berman A.J. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin. Immunopathol. 2008, 30:65-84.
2. Aguilar E., et al. Ocular models of angiogenesis. Methods Enzymol. 2008, 444:115-158. (Chapter 6).
3. Aiello L.P., et al. Diabetic retinopathy. Diabetes Care 1998, 21:143-156.
4. Akula J.D., et al. The neurovascular relation in oxygen-induced retinopathy. Mol. Vis. 2008, 14:2499-2508.
5. Akula J.D., et al. Visual cycle modulation in neurovascular retinopathy. Exp. Eye Res. 2010.
6. Al-Shabrawey M., et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am. J. Pathol. 2005, 167:599-607.
7. Al-Shabrawey M., et al. Role of NADPH oxidase and STAT3 in Statin-mediated protection against diabetic retinopathy. Invest Ophthalmol. Vis. Sci. 2008, 49:3231-3238.
8. Al-Shabrawey M., et al. Role of NADPH oxidase in retinal vascular inflammation. Invest. Ophthalmol. Vis. Sci. 2008, 49:3239-3244.
9. Alon T., et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1995, 1:1024-1028.
10. Amin H.J., et al. Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J.Pediatr. 2002, 140:425-431.
11. Antonetti D.A., et al. Diabetic retinopathy. N.Engl. J. Med. 2012, 366:1227-1239.
12. Ash D.E. Structure and function of arginases. J.Nutr. 2004, 134:2760S-2764S. discussion 2765S-2767S.
13. Ashton N., et al. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br. J. Ophthalmol. 1954, 38:397-432.
14. Ashton H., et al. Therapeutics X. Topical antifungal agents. Br. J. Dermatol. 1970, 82:539-541.
15. Aulak K.S., et al. Proteomic method identifies proteins nitrated invivo during inflammatory challenge. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12056-12061.
16. Aylward G.W. The scotopic threshold response in diabetic retinopathy. Eye (Lond.) 1989, 3(Pt 5):626-637.
17. Bachetti T., et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J.Mol. Cell. Cardiol. 2004, 37:515-523.
18. Bagnost T., et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc. Res. 2010.
19. Barber A.J., et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J.Clin. Invest. 1998, 102:783-791.
20. Barber A.J., et al. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:1156-1163.
21. Barnaby A.M., et al. Development of scotopic visual thresholds in retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2007, 48:4854-4860.
22. Beauchamp M.H., et al. Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. J.Appl. Physiol. 2001, 90:2279-2288.
23. Beckman J.S., et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1620-1624.
24. Berkowitz D.E., et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003, 108:2000-2006.
25. Bhatia S., et al. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin. Biochem. 2003, 36:557-562.
26. Bivalacqua T.J., et al. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of invivo gene therapy of anti-arginase. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1340-H1351.
27. Boor P., et al. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant 2007, 22:3391-3407.
28. Brafman A., et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest. Ophthalmol. Vis. Sci. 2004, 45:3796-3805.
29. Braissant O., et al. L-arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study. Brain Res. Mol. Brain Res. 1999, 70:231-241.
30. Brooks S.E., et al. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest. Ophthalmol. Vis. Sci. 2001, 42:222-228.
31. Buga G.M., et al. NG-hydroxy-L-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. Am. J. Physiol. 1998, 275:R1256-R1264.
32. Bunn H.F. Pathogenesis and treatment of sickle cell disease. N.Engl. J. Med. 1997, 337:762-769.
33. Cao R., et al. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One 2008, 3:e2748.
34. Ceriello A. The emerging challenge in diabetes: the "metabolic memory". Vascul Pharmacol. 2012, 57:133-138.
35. Chandra S., et al. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br. J. Pharmacol. 2012, 165:506-519.
36. Chang C.I., et al. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J.Immunol. 2000, 165:2134-2141.
37. Chen B., et al. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297:L1151-L1159.
38. Cho N.C., et al. Selective loss of S-cones in diabetic retinopathy. Arch. Ophthalmol. 2000, 118:1393-1400.
39. Clermont A.C., Bursell S.E. Retinal blood flow in diabetes. Microcirculation 2007, 14:49-61.
40. Cohen R.A., Tong X. Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. J.Cardiovasc. Pharmacol. 2010, 55:308-316.
41. Cooke J.P., Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu. Rev. Med. 1997, 48:489-509.
42. Cooke J.P., et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J.Clin. Invest. 1991, 88:1663-1671.
43. Cox J.D., et al. Arginase-boronic acid complex highlights a physiological role in erectile function. Nat. Struct. Biol. 1999, 6:1043-1047.
44. Curtis T.M., Scholfield C.N. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab. Res. Rev. 2004, 20:28-43.
45. Curtis T.M., et al. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?. Eye 2009, 23:1496-1508.
46. Darley-Usmar V., et al. Nitric oxide and oxygen radicals: a question of balance. FEBS Lett. 1995, 369:131-135.
47. Davel L.E., et al. Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages. FEBS Lett. 2002, 532:216-220.
48. Davoodi J., et al. Overexpression and characterization of the human mitochondrial and cytosolic branched-chain aminotransferases. J.Biol. Chem. 1998, 273:4982-4989.
49. DCCT The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N.Engl. J. Med. 1993, 329:977-986.
50. de Boer J., et al. Role of nitric oxide and superoxide in allergen-induced airway hyperreactivity after the late asthmatic reaction in guinea-pigs. Br. J. Pharmacol. 2001, 133:1235-1242.
51. De Caterina R., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J.Clin. Invest. 1995, 96:60-68.
52. de Sousa M.S., et al. Arginase 2 and nitric oxide synthase: pathways associated with the pathogenesis of thyroid tumors. Free Radic. Biol. Med. 2010.
53. Deignan J.L., et al. Contrasting features of urea cycle disorders in human patients and knockout mouse models. Mol. Genet. Metab. 2008, 93:7-14.
54. Delage B., et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer 2010, 126:2762-2772.
55. Dembinska O., et al. Graded contribution of retinal maturation to the development of oxygen-induced retinopathy in rats. Invest. Ophthalmol. Vis. Sci. 2001, 42:1111-1118.
56. Dizikes G.J., et al. Isolation of human liver arginase cDNA and demonstration of nonhomology between the two human arginase genes. Biochem. Biophys. Res. Commun. 1986, 141:53-59.
57. Doughan A.K., et al. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ. Res. 2008, 102:488-496.
58. Downie L.E., et al. Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity. J.Comp. Neurol. 2007, 504:404-417.
59. Du Y., et al. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J.Neurochem. 2002, 80:771-779.
60. Durante W., et al. Thrombin stimulates vascular smooth muscle cell polyamine synthesis by inducing cationic amino acid transporter and ornithine decarboxylase gene expression. Circ. Res. 1998, 83:217-223.
61. Durante W., et al. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin. Exp. Pharmacol. Physiol. 2007, 34:906-911.
62. El-Remessy A., Behzadian M.A., Abou-Mohamed G., Franklin T., Caldwell R.W., Caldwell R.B. Peroxynitrite increases vascular permeability in experimental diabetes by a mechanism involving increased expression of VEGF and urokinase plasminogen activator receptor (uPAR). Am. J. Pathol. 2003, 162:1995-2004.
63. 2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic. Biol. Med. 2000, 28:91-101.
64. Elms S.C., et al. The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 2013, 56:654-662.
65. Esch F., et al. Purification of a multipotent antideath activity from bovine liver and its identification as arginase: nitric oxide-independent inhibition of neuronal apoptosis. J.Neurosci. 1998, 18:4083-4095.
66. Fasipe F.R., et al. Arginine supplementation improves rotorod performance in sickle transgenic mice. Hematology 2004, 9:301-305.
67. Filbin M.T. The Muddle with MAG. Mol. Cell. Neurosci. 1996, 8:84-92.
68. Fletcher E.L., et al. The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol. 2010, 120:67-86.
69. Friedlander M. Fibrosis and diseases of the eye. J.Clin. Invest. 2007, 117:576-586.
70. Fulton A.B., Hansen R.M. Electroretinogram responses and refractive errors in patients with a history of retinopathy prematurity. Doc Ophthalmol. 1995, 91:87-100.
71. Fulton A.B., Hansen R.M. Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J.Opt. Soc. Am. A Opt. Image Sci. Vis. 1996, 13:566-571.
72. Fulton A.B., et al. The rod photoreceptors in retinopathy of prematurity: an electroretinographic study. Arch. Ophthalmol. 2001, 119:499-505.
73. Fulton A.B., et al. The neurovascular retina in retinopathy of prematurity. Prog. Retin. Eye Res. 2009, 28:452-482.
74. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
75. Glazer E.S., et al. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011, 4:138-146.
76. Gomes-Trolin C., et al. Increased red blood cell polyamines in ALS and Parkinson's disease. Exp. Neurol. 2002, 177:515-520.
77. Good W.V., Gendron R.L. Retinopathy of prematurity: gone today, here tomorrow?. Clin. Exp. Ophthalmol. 2005, 33:339-340.
78. Gotoh T., et al. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett. 1996, 395:119-122.
79. Gotoh T., et al. Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem. Biophys. Res. Commun. 1997, 233:487-491.
80. Griendling K.K., et al. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 2000, 86:494-501.
81. Gruetter C.A., et al. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J.Cyclic Nucleotide Res. 1979, 5:211-224.
82. Gu X., et al. Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol. Vis. Sci. 2002, 43:496-502.
83. Gualtieri M., et al. Contrast sensitivity mediated by inferred magno- and parvocellular pathways in type 2 diabetics with and without nonproliferative retinopathy. Invest Ophthalmol. Vis. Sci. 2011, 52:1151-1155.
84. Guo X., et al. ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H238-H246.
85. Guzik T.J., Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 2006, 11:524-533.
86. Guzik T.J., et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105:1656-1662.
87. Haffner I., et al. Regulation of arginase-1 expression in macrophages by a protein kinase A type I and histone deacetylase dependent pathway. J.Cell. Biochem. 2008, 103:520-527.
88. Hagenfeldt L., et al. Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr. Scand. 1989, 78:278-282.
89. Hammes H.P., et al. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med. 1995, 1:527-534.
90. Hansen R.M., Fulton A.B. Background adaptation in children with a history of mild retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2000, 41:320-324.
91. Harrison W.W., et al. Prediction, by retinal location, of the onset of diabetic edema in patients with nonproliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2011, 52:6825-6831.
92. Hartnett M.E. Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis). Trans. Am. Ophthalmol. Soc. 2010, 108:96-119.
93. Hayasaka S., et al. Retinal risks of high-dose ornithine supplements: a review. Br. J. Nutr. 2011, 106:801-811.
94. Hayashi T., Iguchi A. Possibility of the regression of atherosclerosis through the prevention of endothelial senescence by the regulation of nitric oxide and free radical scavengers. Geriatr. Gerontol. Int. 2010, 10:115-130.
95. He T., et al. Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice. Arch. Med. Res. 2007, 38:807-815.
96. Hein T.W., et al. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. Faseb J. 2003, 17:2328-2330.
97. Horowitz S., et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G1323-G1336.
98. Huynh N.N., et al. Arginase II knockout mouse displays a hypertensive phenotype despite a decreased vasoconstrictory profile. Hypertension 2009, 54:294-301.
99. Huynh N.N., et al. The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br. J. Pharmacol. 2009, 156:84-93.
100. Inoguchi T., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J.Am. Soc. Nephrol. 2003, 14:S227-S232.
101. Ishizaki E., et al. Functional K(ATP) channels in the rat retinal microvasculature: topographical distribution, redox regulation, spermine modulation and diabetic alteration. J.Physiol. 2009, 587:2233-2253.
102. Ivanova S., et al. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J.Exp. Med. 1998, 188:327-340.
103. Ivanova S., et al. Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:5579-5584.
104. Iyer R.K., et al. Mouse model for human arginase deficiency. Mol. Cell. Biol. 2002, 22:4491-4498.
105. Jackson G.R., et al. Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br. J. Ophthalmol. 2012, 96:699-703.
106. Jeglinski W., et al. Difluoromethylornithine counteracts lesion-induced astrogliosis in rat hippocampus: enhancement of inhibitory effect by combined treatment with GM1 ganglioside. Acta Neurobiol. Exp. (Wars) 1996, 56:549-553.
107. Jeyabalan G., et al. Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide 2008, 19:29-35.
108. Jiang M., et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem. Biophys. Res. Commun. 2003, 309:196-200.
109. Jin Y., et al. Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1518-H1528.
110. Retinal Vascular Diseases 2007, Springer-Verlag, Berlin, Germany. A.M. Joussen (Ed.).
111. Jung C., et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc. Res. 2010, 85:147-154.
112. Kampfer H., et al. Expression and activity of arginase isoenzymes during normal and diabetes-impaired skin repair. J.Invest. Dermatol. 2003, 121:1544-1551.
113. Kapoor M., et al. Effects of epicatechin gallate on wound healing and scar formation in a full thickness incisional wound healing model in rats. Am. J. Pathol. 2004, 165:299-307.
114. Kaur C., et al. Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia. Invest. Ophthalmol. Vis. Sci. 2009, 50:5364-5374.
115. Kenyon N.J., et al. Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences. Toxicol. Appl. Pharmacol. 2008, 230:269-275.
116. Kim J.H., et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J.Appl. Physiol. 2009, 107:1249-1257.
117. Klein R., Klein B.E. Diabetic eye disease. Lancet 1997, 350:197-204.
118. Koga T., et al. Coinduction of nitric oxide synthase and arginine metabolic enzymes in endotoxin-induced uveitis rats. Exp. Eye Res. 2002, 75:659-667.
119. Kowluru R.A., et al. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. Curr. Eye Res. 2000, 21:814-819.
120. Kruman I., et al. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J.Neurosci. 1997, 17:5089-5100.
121. Kuo H.S., et al. The combination of peripheral nerve grafts and acidic fibroblast growth factor enhances arginase I and polyamine spermine expression in transected rat spinal cords. Biochem. Biophys. Res. Commun. 2007, 357:1-7.
122. Kusmartsev S., Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J.Immunol. 2005, 174:4880-4891.
123. Lange P.S., et al. Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. J.Nutr. 2004, 134:2812S-2817S. discussion 2818S-2819S.
124. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010, 460:525-542.
125. Lechner M., et al. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol. 2005, 15:277-289.
126. Li Q., Puro D.G. Adenosine activates ATP-sensitive K(+) currents in pericytes of rat retinal microvessels: role of A1 and A2a receptors. Brain Res. 2001, 907:93-99.
127. Li H., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E75-E82.
128. Lima e Silva R., et al. Suppression and regression of choroidal neovascularization by polyamine analogues. Invest. Ophthalmol. Vis. Sci. 2005, 46:3323-3330.
129. Lima e Silva R., et al. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp. Eye Res. 2006, 83:1260-1267.
130. Lindemann D., Racke K. Glucocorticoid inhibition of interleukin-4 (IL-4) and interleukin-13 (IL-13) induced up-regulation of arginase in rat airway fibroblasts. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368:546-550.
131. Liu K., et al. Development of the electroretinographic oscillatory potentials in normal and ROP rats. Invest. Ophthalmol. Vis. Sci. 2006, 47:5447-5452.
132. Loirand G., et al. Rho exchange factors in the cardiovascular system. Curr. Opin. Pharmacol. 2008, 8:174-180.
133. Lopez-Lopez J.G., et al. Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. American journal of physiology. Lung Cell. Mol. Physiol. 2008, 295:L727-L732.
134. Lovett F.A., et al. Convergence of Igf2 expression and adhesion signalling via RhoA and p38 MAPK enhances myogenic differentiation. J.Cell Sci. 2006, 119:4828-4840.
135. Maarsingh H., et al. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir. Res. 2006, 7:6.
136. Maarsingh H., et al. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 378:171-184.
137. Maarsingh H., et al. Arginine homeostasis in allergic asthma. Eur. J. Pharmacol. 2008, 585:375-384.
138. Madan A., Penn J.S. Animal models of oxygen-induced retinopathy. Front. Biosci. 2003, 8:d1030-d1043.
139. Marrero M.B., et al. Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J.Biol. Chem. 1997, 272:24684-24690.
140. Masuda H., et al. Modulation of intrinsic cavernous tone and nitric oxide production by arginase in rabbit corpus cavernosum. J.Urol. 2004, 171:490-494.
141. Matsushita K., Puro D.G. Topographical heterogeneity of K(IR) currents in pericyte-containing microvessels of the rat retina: effect of diabetes. J.Physiol. 2006, 573:483-495.
142. McCracken E., et al. The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. J.Cereb. Blood Flow Metab. 2000, 20:1529-1536.
143. McLeod D.S., et al. Clinical and histopathologic features of canine oxygen-induced proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 1998, 39:1918-1932.
144. Merzouk S., et al. Antioxidant status and levels of different vitamins determined by high performance liquid chromatography in diabetic subjects with multiple complications. Gen. Physiol. Biophys. 2003, 22:15-27.
145. Meurs H., et al. Airway hyperresponsiveness in asthma: lessons from invitro model systems and animal models. Eur. Respir. J. 2008, 32:487-502.
146. Mills C.D., et al. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J.Immunol. 1992, 149:2709-2714.
147. Ming X.F., et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004, 110:3708-3714.
148. Mintz-Hittner H.A., et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N.Engl. J. Med. 2011, 364:603-615.
149. Miyanaka K., et al. Immunohistochemical localization of arginase II and other enzymes of arginine metabolism in rat kidney and liver. Histochem. J. 1998, 30:741-751.
150. Morris S.M. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 2002, 22:87-105.
151. Morris S.M. Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol. 2009, 157:922-930.
152. Morris C.R., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. Jama 2005, 294:81-90.
153. Morris C.R., et al. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr. Mol. Med. 2008, 8:620-632.
154. Morrison L.D., Kish S.J. Brain polyamine levels are altered in Alzheimer's disease. Neurosci. Lett. 1995, 197:5-8.
155. Mumenthaler S.M., et al. Expression of arginase II in prostate cancer. Int. J. Oncol. 2008, 32:357-365.
156. Munder M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 2009, 158:638-651.
157. Nagaoka T., et al. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry study. Invest Ophthalmol. Vis. Sci. 2010, 51:6729-6734.
158. Nakamura S., et al. Morphological and functional changes in the retina after chronic oxygen-induced retinopathy. PLoS One 2012, 7:e32167.
159. Narayanan S.P., et al. Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS One 2011, 6:e22460.
160. Narayanan, S.P., et al., 2013. Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism (submitted for publication).
161. Narita Y., et al. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J.Immunol. 2012, 190:812-820.
162. NEI The Prevalence of Diabetic Retinopathy Among Adults in the United States 2008, http://www.nei.nih.gov/eyedata/pbd3.asp.
163. Neu J. Glutamine supplements in premature infants: why and how. J.Pediatr. Gastroenterol. Nutr. 2003, 37:533-535.
164. Neu J., et al. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol. Vis. Sci. 2006, 47:3151-3155.
165. Neufeld A.H., et al. Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase. Exp. Eye Res. 2002, 75:521-528.
166. Nicholson B.P., Schachat A.P. Areview of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:915-930.
167. Nicoletti R., et al. Vitreous polyamines spermidine, putrescine, and spermine in human proliferative disorders of the retina. Br. J. Ophthalmol. 2003, 87:1038-1042.
168. Niesman M.R., et al. Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem. Res. 1997, 22:597-605.
169. Nishikawa T., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
170. O'Connor A.R., et al. Long-term ophthalmic outcome of low birth weight children with and without retinopathy of prematurity. Pediatrics 2002, 109:12-18.
171. Oguni M., et al. Ontogeny of copper-zinc and manganese superoxide dismutase in the developing rat retina: immunohistochemical and immunochemical study. Ophthalmic Res. 1995, 27:227-233.
172. Ong W.Y., et al. Kainate-induced neuronal injury leads to persistent phosphorylation of cAMP response element-binding protein in glial and endothelial cells in the hippocampus. Exp. Brain Res. 2000, 131:178-186.
173. Osborne N.N., et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 2004, 23:91-147.
174. Osowska S., et al. Citrulline increases arginine pools and restores nitrogen balance after massive intestinal resection. Gut 2004, 53:1781-1786.
175. Ozaki M., et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J.Clin. Invest. 2002, 110:331-340.
176. Pacher P., et al. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87:315-424.
177. Park H.Y., et al. Early diabetic changes in the nerve fibre layer at the macula detected by spectral domain optical coherence tomography. Br. J. Ophthalmol. 2011, 95:1223-1228.
178. Patel C., et al. Arginase as a mediator of diabetic retinopathy. Front. Inflamm. 2013, (in press).
179. Penn J.S., et al. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest. Ophthalmol. Vis. Sci. 1993, 34:576-585.
180. Pernet V., et al. Arole for polyamines in retinal ganglion cell excitotoxic death. J.Neurochem. 2007, 103:1481-1490.
181. Pieper G.M., Dondlinger L.A. Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J.Pharmacol. Exp. Ther. 1997, 283:684-691.
182. Pierce E.A., et al. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 1996, 114:1219-1228.
183. Pocernich C.B., Butterfield D.A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res. 2003, 5:515-520.
184. Pollan C. Retinopathy of prematurity: an eye toward better outcomes. Neonatal. Netw. 2009, 28:93-101.
185. Prager T.C., et al. The pattern electroretinogram in diabetes. Am. J. Ophthalmol. 1990, 109:279-284.
186. Reid K.M., et al. Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA). Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G512-G517.
187. Retnakaran R., Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 2008, 371:1790-1799.
188. Rivera J.C., et al. Understanding retinopathy of prematurity: update on pathogenesis. Neonatology 2011, 100:343-353.
189. Romero M.J., et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ. Res. 2008, 102:95-102.
190. Romero M.J., et al. Diabetes-induced vascular dysfunction involves arginase I. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H159-H166.
191. Roth S., et al. Ischemia induces significant changes in purine nucleoside concentration in the retina-choroid in rats. Exp. Eye Res. 1997, 65:771-779.
192. Ryoo S., et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ. Res. 2006, 99:951-960.
193. Ryoo S., et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ. Res. 2008, 102:923-932.
194. Sabbatini M., et al. Arginase inhibition slows the progression of renal failure in rats with renal ablation. Am. J. Physiol. Ren. Physiol. 2003, 284:F680-F687.
195. Santhanam L., et al. Arginase and vascular aging. J.Appl. Physiol. 2008, 105:1632-1642.
196. Santos J.M., et al. Diabetic retinopathy, superoxide damage and antioxidants. Curr. Pharm. Biotechnol. 2011, 12:352-361.
197. Sapieha P., et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J.Clin. Invest. 2010, 120:3022-3032.
198. Satriano J. Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids 2004, 26:321-329.
199. Schieffer B., et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ. Res. 2000, 87:1195-1201.
200. Schwartz I.F., et al. Augmented arginine uptake, through modulation of cationic amino acid transporter-1, increases GFR in diabetic rats. Kidney Int. 2004, 65:1311-1319.
201. Suwanpradid, J., et al., 2013. Arginase 2 deficiency limits hyperoxia-induced oxidative stress and reduces retinal vascular degeneration (submitted for publication).
202. Seiler N. Oxidation of polyamines and brain injury. Neurochem. Res. 2000, 25:471-490.
203. Sennlaub F., et al. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J.Clin. Invest. 2001, 107:717-725.
204. Sennlaub F., et al. Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. J.Neurosci. 2002, 22:3987-3993.
205. Shantz L.M., Levin V.A. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 2007, 33:213-223.
206. Shatanawi A., et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am. J. Physiol. Cell Physiol. 2011, 300:C1181-C1192.
207. Shearer J.D., et al. Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am. J. Physiol. 1997, 272:E181-E190.
208. Singh R., et al. Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res. 2000, 60:3305-3312.
209. Sinha P., et al. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J.Immunol. 2005, 174:636-645.
210. Smith L.E., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol. Vis. Sci. 1994, 35:101-111.
211. Smith L.E., et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709.
212. Smith G., et al. Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br. J. Ophthalmol. 1999, 83:486-494.
213. Sonta T., et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic. Biol. Med. 2004, 37:115-123.
214. Sparkes R.S., et al. The gene for human liver arginase (ARG1) is assigned to chromosome band 6q23. Am. J. Hum. Genet. 1986, 39:186-193.
215. Stempin C.C., et al. Arginase induction promotes Trypanosoma cruzi intracellular replication in Cruzipain-treated J774 cells through the activation of multiple signaling pathways. Eur. J. Immunol. 2004, 34:200-209.
216. Stevenson L., et al. Reduced nitro-oxidative stress and neural cell death suggests a protective role for microglial cells in TNFalpha-/- mice in ischemic retinopathy. Invest Ophthalmol. Vis. Sci. 2010, 51:3291-3299.
217. Takano K., et al. Neuronal and glial responses to polyamines in the ischemic brain. Curr. Neurovasc Res. 2005, 2:213-223.
218. Takano K., et al. Oxidative metabolites are involved in polyamine-induced microglial cell death. Neuroscience 2005, 134:1123-1131.
219. Takki K. Gyrate atrophy of the choroid and retina associated with hyperornithinaemia. Br. J. Ophthalmol. 1974, 58:3-23.
220. Tang J., Kern T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30:343-358.
221. Tawfik H.E., et al. Simvastatin improves diabetes-induced coronary endothelial dysfunction. J.Pharmacol. Exp. Ther. 2006, 319:386-395.
222. Thengchaisri N., et al. Upregulation of arginase by H2O2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb. Vasc. Biol. 2006, 26:2035-2042.
223. Tomitori H., et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 2005, 36:2609-2613.
224. Toque H.A.F., et al. Arginase II deletion increases Corpora Cavernosa relaxation in diabetic mice. J.Sex Med. 2011 2010, 8(3):722-733.
225. UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
226. Vessey K.A., et al. Characterization of retinal function and glial cell response in a mouse model of oxygen-induced retinopathy. J.Comp. Neurol. 2011, 519:506-527.
227. Vlassara H., Palace M.R. Diabetes and advanced glycation endproducts. J.Intern. Med. 2002, 251:87-101.
228. Waddington S.N., et al. Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. Am. J. Physiol. 1998, 274:F473-F480.
229. Waugh W.H., et al. Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results. J.Natl. Med. Assoc. 2001, 93:363-371.
230. Wei L.H., et al. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2000, 279:C248-C256.
231. Weigert A., Brune B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 2008, 19:95-102.
232. White A.R., et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006, 47:245-251.
233. Witte M.B., Barbul A. Arginine physiology and its implication for wound healing. Wound Repair Regen. 2003, 11:419-423.
234. Wong T.Y., Scott I.U. Clinical practice. Retinal-vein occlusion. N.Engl. J. Med. 2010, 363:2135-2144.
235. Wood P.L., et al. Neurotoxicity of reactive aldehydes: the concept of "aldehyde load" as demonstrated by neuroprotection with hydroxylamines. Brain Res. 2006, 1095:190-199.
236. Wu G., et al. Arginine deficiency in preterm infants: biochemical mechanisms and nutritional implications. J.Nutr. Biochem. 2004, 15:442-451.
237. Wu W.C., et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology 2012, 119:1907-1916.
238. Xia Y., Zweier J.L. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6954-6958.
239. Xu W., et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004, 18:1746-1748.
240. Yamakura F., et al. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J.Biol. Chem. 1998, 273:14085-14089.
241. Yamamoto S., et al. Selective reduction of the S cone electroretinogram in diabetes. Br. J. Ophthalmol. 1996, 80:973-975.
242. Yang Z., Ming X.F. Endothelial arginase: a new target in atherosclerosis. Curr. Hypertens. Rep. 2006, 8:54-59.
243. Yang M., et al. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J.Immunol. 2006, 177:5595-5603.
244. Yokota H., et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Invest. Ophthalmol. Vis. Sci. 2011, 52:8123-8131.
245. Yoshida M., et al. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis 2009, 203:557-562.
246. Yu Z., et al. 3-Aminopropanal is a lysosomotropic aldehyde that causes oxidative stress and apoptosis by rupturing lysosomes. Apmis 2003, 111:643-652.
247. Yu Z., et al. Human neuroblastoma (SH-SY5Y) cells are highly sensitive to the lysosomotropic aldehyde 3-aminopropanal. Brain Res. 2004, 1016:163-169.
248. Zahedi K., et al. Polyamine catabolism is enhanced after traumatic brain injury. J.Neurotrauma 2010, 27:515-525.
249. Zhang C., et al. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J. 2001, 15:1264-1266.
250. Zhang W., et al. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am. J. Pathol. 2009, 175:891-902.
251. Zhang W., et al. NAD(P)H oxidase-dependent regulation of CCL2 production during retinal inflammation. Invest. Ophthalmol. Vis. Sci. 2009, 50:3033-3040.
252. Zharikov S., et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am. J. Physiol. Cell Physiol. 2008, 295:C1183-C1190.
253. Zimmermann N., et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J.Clin. Invest. 2003, 111:1863-1874.